ArticleFrontiers in endocrinology2025
Association between abnormal glycoprotein and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: To investigate the association between serum abnormal glycoprotein (AP) and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM). Materials and methods: This cross-sectional study enrolled 476 patients with T2DM. DPN was diagnosed using the Toronto Clinical Neuropathy Score (TCNS) and nerve conduction studies. The association between AP and DPN was evaluated using multivariable logistic regression, restricted cubic spline analysis (RCS), and receiver operating characteristic (ROC) curve analysis. Results: Serum AP levels were significantly higher in patients with DPN than in those without (P < 0.001). After adjusting for multiple confounders, elevated AP emerged as an independent risk indicator for DPN (OR = 1.024, 95% CI: 1.012-1.036). A non-linear relationship was observed, with a marked increase in DPN risk when AP levels exceeded an inflection point of 119.628 μm². Combining AP with clinical variables significantly enhanced predictive accuracy for DPN, increasing the area under the curve (AUC) from 0.686 to 0.805. Conclusions: Elevated serum AP represents a novel and independent risk indicator for DPN in patients with T2DM. Its integration into clinical practice may facilitate early detection for DPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.